

The CHOICE Institute @ ISPOR 2026

May 17 – 20, 2026

Pennsylvania Convention Center | Philadelphia, PA

<https://www.ispor.org/>

All times listed are Eastern Daylight Time

SUNDAY, MAY 17, 2026

1:00 PM – 5:00 PM: SHORT COURSE AFTERNOON SESSION

Societal Valuation of Innovative Medicines: Emphasis on Investment Perspective and Orphan Disease

Location: Room 204B, Level 200

Faculty: **Lou Garrison, PhD (CHOICE Core Faculty)**, The CHOICE Institute, Seattle, WA, United States; Marlene Gyldmark, MPhil, BeiGene, Basel, Switzerland; Mark J Nuijten, MBA, PhD, MD, A2M, Amsterdam, Netherlands.

6:00 PM – 8:00 PM: ISPOR AWARDS CEREMONY

Location: Notary Hotel Philadelphia; Room: Juniper Ballroom, Mezzanine Level

Join us in celebrating **Dr. Sean D. Sullivan, BScPharm, MSc, PhD (CHOICE Core Faculty)** for receiving the [Avedis Donabedian Lifetime Achievement Award!](#)

MONDAY, MAY 18, 2026

10:30 AM – 11:30 AM: CONCURRENT BREAKOUT SESSIONS 1

Value-Based Pricing for CMS Drug Price Negotiation: Mission Impossible?

Location: Room 113ABC, Level 100

Moderator: Peter Neumann, ScD, Tufts Medical Center, Boston, MA.

Speakers: Feng Xie, PhD, McMaster University, Hamilton, ON, Canada; **Sean D Sullivan, PhD (CHOICE Core Faculty)**, University of Washington, Seattle, WA; Joshua Cohen, PhD, Tufts Medical Center, Boston, MA.

12:30 PM – 1:30 PM: POSTER SESSION 1 DISCUSSION HOUR

Location: Poster & Exhibit Hall, Hall A, Level 200

Full Poster Session Time: 10:30 AM – 1:30 PM

Shiven Bhardwaj, CHOICE PhD Candidate (Poster 1)

HSD13: COMPARISON OF GUIDELINE-RECOMMENDED AND PRELIMINARY RISK-BASED APPROACHES TO SELECTION OF LUNG CANCER PATIENTS FOR LYMPH NODE STAGING

Topic: Health Service Delivery & Process of Care

Disease: SDC: Oncology

Shiven Bhardwaj, CHOICE PhD Candidate (Poster 2)

EE21: FINANCIAL COSTS OF PROVIDING ORAL PRE- AND POST-EXPOSURE PROPHYLAXIS VIA PHARMACIES IN KENYA

Topic: Economic Evaluation; Cost/Cost of Illness/Resource Use Studies

Disease: SDC: Infectious Disease (non-vaccine)

Greg Guzauskas, CHOICE Senior Research Scientist

EE44: COST-EFFECTIVENESS OF POLYGENIC RISK-GUIDED BREAST CANCER SCREENING WITH AND WITHOUT HBOC TESTING: A DISCRETE-EVENT SIMULATION WITH PROBABILISTIC SENSITIVITY ANALYSIS

Topic: Economic Evaluation

Disease: No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology, STA: Genetic, Regenerative & Curative Therapies, STA: Personalized & Precision Medicine

Ben Nwogu, CHOICE PhD Candidate (Poster 1)

[CO24: REAL-WORLD COMPARATIVE EFFECTIVENESS OF LUTETIUM-177-PSMA-617 VERSUS CABAZITAXEL FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER](#)

Topic: Clinical Outcomes; Comparative Effectiveness or Efficacy

Disease: SDC: Oncology

Ben Nwogu, CHOICE PhD Candidate (Poster 2)

[EE46: COST-EFFECTIVENESS OF ABIRATERONE, APALUTAMIDE, ENZALUTAMIDE, AND DOCETAXEL DOUBLET FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: A REAL-WORLD EVIDENCE ANALYSIS](#)

Topic: Economic Evaluation

Disease: SDC: Oncology

Ruihan (Helen) Qin, CHOICE PhD Student

[HPR30: VALUE-BASED PURCHASING ARRANGEMENTS IN MEDICAID: A TARGETED LITERATURE REVIEW](#)

Topic: Health Policy & Regulatory; Risk-sharing Approaches

Disease: No Additional Disease & Conditions/Specialized Treatment Areas

Scott Ramsey, CHOICE Adjunct Faculty

[PCR19: DOES SUBSTANDARD CANCER CARE ADVERSELY IMPACT PATIENT FINANCIAL WELL BEING? AN ANALYSIS OF CANCER REGISTRY, CLAIMS, AND CREDIT REPORT SCORES](#)

Topic: Patient-Centered Research; Adherence, Persistence, & Compliance

Disease: No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology

12:15 PM – 1:15 PM: EDUCATIONAL SYMPOSIA

[Measuring What Matters: Broader Value Elements in HTA and Their Impact on Access](#)

Location: Michael Nutter Theater, Level 100

Moderator: Graham Cookson, MA, MSc, PhD, Office of Health Economics, London, United Kingdom.

Speakers: Oriol de Sola-Morales, MSc, PhD, MD, Fundacio HiTT, Barcelona, Spain; **Lotte Steuten, MSc, PhD (CHOICE Affiliate Faculty)**, Office of Health Economics, London, United Kingdom; Jon Tosh, BA, MSc,

PhD, ViiV Healthcare, London, United Kingdom; Jon D Campbell, MS, PhD, National Pharmaceutical Council, Washington, DC.

3:15 PM – 4:15 PM: FORUMS

Good Practices Reports in Action: Advancing Evidence for Policy, Access, and Value

Location: Bridge Over Arch West, Level 200

Moderator: Elizabeth Molsen-David, RN, ISPOR, Lawrenceville, NJ.

Speakers: Onyeka Illoh, MPH, PhD, U.S. FDA, Silver Spring, MD; **Jens Grueger, PhD (CHOICE Affiliate Faculty)**, Boston Consulting Group, Freiburg, Germany; Louis Matza, PhD, Thermo Fisher Scientific, Bethesda, MD; Dan Ollendorf, MPH, PhD, Institute for Clinical and Economic Review (ICER), Boston, MA.

4:15 PM – 5:15 PM: MEMBER GROUP MEETINGS

Frontiers in Health Decision Modeling: A Dialogue With ISPOR and SMDM

Location: Room 106AB, Level 100

Speakers: Uwe Siebert, MPH, MSc, ScD, MD, UMIT TIROL - University for Health Sciences and Technology; Harvard Chan School of Public Health, Hall in Tirol, Austria; **Beth Devine, MBA, MSc, PharmD, PhD (CHOICE Core Faculty & ISPOR President)**, University of Washington, Seattle, WA; Laura Pizzi, MPH, PharmD, ISPOR, Lawrenceville, NJ.

5:00 PM – 7:00 PM: CHOICE ALUMNI & FRIENDS HAPPY HOUR

Location: [Brü Craft & Wurst](#) | 1318 Chestnut Street, Philadelphia, PA 19107

6:00 PM – 7:00 PM: POSTER SESSION 2 DISCUSSION PERIOD

Location: Poster & Exhibit Hall, Hall A, Level 200

Full Poster Session Time: 4:00 PM – 7:00 PM

Emma Cousin, CHOICE PhD Candidate

HPR57: ASSESSMENT OF IPAY 2027 MEDICARE DRUG PRICE NEGOTIATION MAXIMUM FAIR PRICES WITH PRICES IN MOST FAVORED NATION REFERENCE COUNTRIES

Topic: Health Policy & Regulatory; Pricing Policy & Schemes

Disease: No Additional Disease & Conditions/Specialized Treatment Areas

Rachel Kneitel, UW/AbbVie HEOR Fellow

CO69: HEALTHCARE RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH AML TREATED WITH POST-TRANSPLANT MAINTENANCE THERAPY

Topic: Clinical Outcomes; Comparative Effectiveness or Efficacy
Disease: Oncology, STA: Multiple/Other Specialized Treatments

Jonathan Luong, UW/Genentech HEOR Fellow

EE148: COST-EFFECTIVENESS OF NEOADJUVANT AND ADJUVANT PEMBROLIZUMAB IN LOCALLY ADVANCED HEAD AND NECK CANCER

Topic: Economic Evaluation
Disease: SDC: Oncology

Jacob Vang, UW/Pfizer HEOR Fellow

EE147: COST EFFECTIVENESS OF EARLY VS DELAYED AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA

Topic: Economic Evaluation
Disease: No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology

TUESDAY, MAY 19, 2026

8:30 AM – 10:00 AM: PLENARY SESSIONS

Presidential Addresses, Special Address, and Awards

Location: Ballroom AB, Level 300

Speakers: Uwe Siebert, MPH, MSc, ScD, MD, UMIT TIROL - University for Health Sciences and Technology; Harvard Chan School of Public Health, Hall in Tirol, Austria; **Beth Devine, MBA, MSc, PharmD, PhD (CHOICE Core Faculty and ISPOR President)**, University of Washington, Seattle, WA; Dawn Hershman, MD, MS, FASCO, Columbia University Medical Center, New York, NY.

The True Cost of Cancer: Aligning Innovation, Access, and Affordability

Location: Ballroom AB, Level 300

Moderator: **Scott Ramsey, PhD, MD (CHOICE Adjunct Faculty)**, Fred Hutchinson Cancer Research Center, Seattle, WA.

Speakers: Dawn Hershman, MD, MS, FASCO, Columbia University Medical Center, New York, NY; Stacie Dusetzina, PhD, Vanderbilt University Medical Center, Nashville, TN; Bobby Green, MD, ThymeCare, Nashville, TN.

10:30 AM – 11:30 AM: CONCURRENT BREAKOUT SESSIONS 4

Including Equity in Health Technology Assessment: DCEA, Social Welfare Functions, and Inequality-Aversion Approaches

Location: Room 103BC, Level 100

Moderator: **Lou Garrison, PhD (CHOICE Core Faculty)**, University of Washington, Seattle, WA.

Speakers: Susan Griffin, PhD, University of York, York, United Kingdom; Charles E Phelps, MBA, PhD, University of Rochester, Pittsford, NY; Ian J Davis, MA, University of Southern California, Los Angeles, CA.

12:15 PM – 1:15 PM: FORUMS

Advancements in Real-World Evidence (RWE) to Accelerate Access in Rare Cancers: Challenges, Methods, and Decision Making

Location: Room 108AB, Level 100

Moderator: Shilpi Swami, ConnectHEOR, London, United Kingdom.

Speakers: Sandipan Bhattacharjee, MS, PhD, Bayer U.S. LLC, Belle Mead, NJ; Diana Brixner, RPh, PhD, University of Utah, Salt Lake City, UT; **Scott Ramsey, PhD, MD (CHOICE Adjunct Faculty)**, Fred Hutchinson Cancer Research Center, Seattle, WA.

12:30 PM – 1:30 PM: POSTER SESSION 3 DISCUSSION PERIOD

Location: Poster & Exhibit Hall, Hall A, Level 200
Full Poster Session Time: 10:30 AM – 1:30 PM

Andrew Cotterill, UW/AbbVie HEOR Fellow

[MSR109: DETERMINING AN ECONOMICALLY JUSTIFIABLE PRICE FOR TRONTINEMAB IN EARLY ALZHEIMER'S DISEASE](#)

Topic: Methodological & Statistical Research
Disease: SDC: Neurological Disorders

Divya Jain, UW/Genentech HEOR Fellow

[SA27: UNDERSTANDING THE IMPACT AND BURDEN OF MENOPAUSE ON MULTIPLE SCLEROSIS THROUGH A TARGETED LITERATURE REVIEW](#)

Topic: Study Approaches; Literature Review & Synthesis
Disease: SDC: Neurological Disorders, SDC: Reproductive & Sexual Health

Janice Jang, UW/AbbVie HEOR Fellow

[EE288: COST-EFFECTIVENESS OF REMIBRUTINIB FOR MODERATE TO SEVERE CHRONIC SPONTANEOUS URTICARIA IN THE U.S.](#)

Topic: Economic Evaluation
Disease: SDC: Sensory System Disorders (Ear, Eye, Dental, Skin)

Jean Lee, UW/Bayer HEOR Fellow

[EE215: INCIDENCE AND COSTS OF SECONDARY STROKE EVENTS IN PATIENTS WITH ISCHEMIC STROKE OR TRANSIENT ISCHEMIC ATTACK OF NON-CARDIOEMBOLIC ORIGIN](#)

Topic: Economic Evaluation; Cost/Cost of Illness/Resource Use Studies
Disease: SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory)

Kathryn Perkins, UW/Pfizer HEOR Fellow

[EE259: MEASURING THE IMPACT OF CACHEXIA ON RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH PANCREATIC, LUNG, AND COLORECTAL CANCERS IN THE UNITED STATES: A CLAIMS DATABASE ANALYSIS](#)

Topic: Economic Evaluation; Cost/Cost of Illness/Resource Use Studies

Nissen Weisman, UW/Genentech HEOR Fellow

[EE265: COST-EFFECTIVENESS OF LAZERTINIB-AMIVANTAMAB COMPARED TO OSIMERTINIB FOR NON-SMALL CELL LUNG CANCER: A 5-YEAR PARTITIONED SURVIVAL MODEL](#)

Topic: Economic Evaluation

Disease: No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology

1:45 PM – 2:45 PM: CONCURRENT BREAKOUT SESSIONS 5

[HEOR as a Compass, Not a Roadblock: How and When Development-Stage Biotech Companies Should Leverage HEOR](#)

Location: Michael Nutter Theater, Level 100

Moderator: **William J Canestaro, MS, PhD (CHOICE Affiliate Faculty & PhD Alum)**, University of Washington, Seattle, WA.

Speakers: **Zsolt Hepp, MS, PharmD (CHOICE Affiliate Faculty & PhD Alum)**, Immunome, Kirkland, WA; Neal Masia, PhD, EntityRisk, Inc., Princeton, NJ; Amanda Cole, BSc, PhD, Office of Health Economics, London, United Kingdom; Zachary Strasser, Patient Square Capital, Menlo Park, CA.

[Pursuing Affordability Decision Rules: Towards Transparent, Evidence-Informed Budget Impact Thresholds](#)

Location: Room 204A-C, Level 200

Moderator: **Lotte Steuten, MSc, PhD (CHOICE Affiliate Faculty)**, Office of Health Economics, London, United Kingdom.

Speakers: **Scott Ramsey, PhD, MD (CHOICE Adjunct Faculty)**, Fred Hutchinson Cancer Research Center, Seattle, WA; Jeffrey T. Hamilton, BA, MSc, GSK, Westfield, NJ; Marina Richardson, Institute for Clinical and Economic Review (ICER), Boston, MA.

4:45 PM – 5:45 PM: CONCURRENT BREAKOUT SESSIONS 6

Can New Approaches to Estimating Dynamic Efficiency Help to Maintain Both Access and Innovation in Pharmaceutical Markets?

Location: Room 201BC, Level 200

Moderator: Robert J Nordyke, BS, MS, PhD, BlueRidge Life Sciences, Topanga, CA.

Speakers: Robert B McQueen, BA, MA, PhD, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Science, Aurora, CO; **Anirban Basu, PhD (CHOICE Core Faculty & Director)**, University of Washington, Seattle, WA; Julie Patterson, PharmD, PhD, National Pharmaceutical Council, Washington, DC.

Advancing HEOR With Next-Generation AI: Multimodal LLMs, Digital Twins, and Reinforcement Learning for Personalized Therapy

Location: Room 201AB, Level 200

Moderator: **Zachary Marcum, PharmD, PhD (CHOICE Affiliate Faculty)**, Medicus Economics, Hamilton, OH.

Speakers: Weihsuan J Lo-Ciganic, MS, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA; Marc Y Tian, PhD, Teva Pharmaceuticals, Skillman, NJ; Cheng Peng, PhD, University of Florida, Department of Health Outcomes and Biomedical Informatics, Gainesville, FL.

6:00 PM – 7:00 PM: POSTER SESSION 4 DISCUSSION PERIOD

Location: Poster & Exhibit Hall, Hall A, Level 200

Full Poster Session Time: 4:00 PM – 7:00 PM

Hui-Hsuan Chan, CHOICE PhD Student

EE362: COST-EFFECTIVENESS OF INTEGRATING BREAST CANCER SCREENING INTO AN EXISTING CERVICAL CANCER SCREENING PROGRAM IN CAMEROON

Topic: Economic Evaluation

Disease: No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology

Satoshi Koiso, CHOICE PhD Student

EE329: COST-EFFECTIVENESS ANALYSIS OF GLP-1 RA TO PREVENT TYPE 2 DIABETES AMONG TEENAGERS IN THE UNITED STATES

Topic: Economic Evaluation

Disease: SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity), SDC: Pediatrics

Nissen Weisman, UW/Genentech HEOR Fellow

CO147: NOVEL THERAPIES FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA POST BRUTON'S TYROSINE KINASE INHIBITOR: A TARGETED LITERATURE REVIEW

Topic: Clinical Outcomes; Comparative Effectiveness or Efficacy

Disease: No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology

WEDNESDAY, MAY 20, 2026

9:00 AM – 10:00 AM: POSTER SESSION 5 DISCUSSION PERIOD

Location: Poster & Exhibit Hall, Hall A, Level 200

Full Poster Session Time: 9:00 AM – 11:30 AM

Beth Devine, CHOICE Core Faculty

[HTA83: ENSURING STUDY VALIDITY TO INFORM HEALTH TECHNOLOGY ASSESSMENTS GLOBALLY](#)

Topic: Health Technology Assessment

Disease: No Additional Disease & Conditions/Specialized Treatment Areas

Lijia Zheng, CHOICE PhD Student

[EE471: COST-EFFECTIVENESS OF AMIVANTAMAB PLUS LAZERTINIB FOR FIRST-LINE TREATMENT OF EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER: A U.S. PAYER PERSPECTIVE](#)

Topic: Economic Evaluation; Thresholds & Opportunity Cost, Trial-Based Economic Evaluation

Disease: SDC: Oncology

Fangzhe Sam Han, CHOICE PhD Student

[HPR151: TARGETED REVIEW FOR OUTCOME-BASED CONTRACTING FRAMEWORKS](#)

Topic: Health Policy & Regulatory

Disease: No Additional Disease & Conditions/Specialized Treatment Areas

10:00 AM – 11:00 AM: CONCURRENT BREAKOUT SESSIONS 8

[Spotlight Session- Beyond Black Boxes: Case Studies of Transparent, Validated LLM Workflows for Accelerating Global HTA Submissions and Decisions](#)

Location: Room 113ABC, Level 100

Moderator: **Beth Devine, MBA, MSc, PharmD, PhD (CHOICE Core Faculty & ISPOR President)**, University of Washington, Seattle, WA.

Speakers: Bill Malcolm, MSc, Bristol Myers Squibb, Middlesex, United Kingdom; Tim Reason, MSc, Estima Scientific, London, United Kingdom; Lockwood Taylor, MPH, PhD, Flatiron Health, Austin, TX.

From Debate to Dialogue: Building Consensus on Prior Authorization Reform

Location: Room 103BC, Level 100

Moderator: Kimberly Westrich, MA, National Pharmaceutical Council, Herndon, VA.

Speakers: **John Watkins, MPH, PharmD (CHOICE Affiliate Faculty)**, University of Washington, Bothell, WA; James Chambers, MSc, PhD, Tufts Medical Center, Boston, MA; Anna Hyde, MA, Arthritis Foundation, Silver Spring, MD.

10:00 AM – 11:00 AM: PODIUM SESSIONS

Access: Pricing, Policy, and Market Dynamics

Karris Jeon (CHOICE PhD Candidate)

P58: PROJECTED MEDICARE DRUG PRICE NEGOTIATION SAVINGS IN 2027

Location: Theater 1, Poster & Exhibit Hall, Hall A, Level 200

11:30 AM – 1:00 PM: CLOSING PLENARY SESSION

Location: Ballroom AB, Level 300

Plenary Session: Innovation Under Pressure: How Will US Drug Policy Reshape Innovation, Evidence, and Access Globally?

Moderator: Indranil Bagchi, MS, PhD, GSK US, Collegeville, PA

Speakers: **Lotte Steuten, MSc, PhD (CHOICE Affiliate Faculty)**, Office of Health Economics, London, United Kingdom; Darius Lakdawalla, PhD, University of Southern California, Los Angeles, CA; **Jens Grueger, PhD (CHOICE Affiliate Faculty)**, Boston Consulting Group, Freiburg, Germany; Lizheng Shi, PhD, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA.